Table 1: Demographic characteristics of patients with posttransplant MN.

VariablesN = 41

Recipient gender – male, n(%)24 (58.5)
Recipient age (years), mean ± DP49.4 ± 13.2
Pretransplant dialysis, n(%)40 (97.5)
Time on dialysis (months), mean ± DP22.6 ± 24.1 (median = 16)
Etiology of end-stage renal disease, n(%)
Membranous nephropathy15 (36.6)
Lupus nephritis2 (4.9)
Unknown9 (22)
Chronic glomerulonephritis5 (12.2)
Hypertension5 (12.2)
Diabetes2 (4.9)
Chronic pyelonephritis1 (2.4)
Urological 1 (2.4)
Cortical necrosis1 (2.4)
Panel reactive antibodies (%), mean ± DP7.85 ± 22.6 (median = 0)
Donor source, n(%)
Living26 (63.4)
  HLA identical6 (14.6)
  HLA haploidentical16 (39)
  HLA distinct4 (9.8)
Deceased15 (36.6)
  Standard criteria donor10 (24.4)
  Expanded criteria donor15 (12.2)
Donor age (years), mean ± DP38.1 ± 16.3
HLA mismatches, mean ± DP2.3 ± 1.8
Cold ischemia time (hours), mean ± DP25 ± 9
Induction therapy, n(%)
None32 (78.1)
Basiliximab1 (2.4)
Thymoglobulin8 (19.5)
Initial immunosuppressive regimen, n(%)
CNI-PRED-AZA23 (56.1)
CNI-PRED-MPA14 (34.1)
CNI PRED-SRL4 (9.8)

PRED: prednisone; CNI: calcineurin inhibitor; AZA: azathioprine; MPA: mycophenolic acid; SRL: sirolimus; HLA: human leukocyte antigens.
1United Network for Organ Sharing (UNOS) criteria [13].